Mereo has been preparing alvelestat for a global Phase III study, supported by positive efficacy data from two Phase II studies. "We are very pleased to have the opportunity to partner with Sentynl to advance alvelestat for patients with AATD-LD. We have been preparing alvelestat for a global Phase III study, backed by positive efficacy data from two Phase II studies. For Sentynl, the agreement extends a rare disease strategy built around ultra-rare conditions into a larger patient population. "This partnership marks a pivotal moment for Sentynl's rare disease strategy.